Close Menu

KRAS Biomarkers

News and reporting on KRAS biomarkers.

In a study published in the Journal of Clinical Oncology, partial responses were observed in patients with BRAF V600-mutated and KRAS-mutated solid tumors.

RMC-4630 will be investigated in combination with an investigational ERK inhibitor in RAS-mutated solid tumors.

The company has seen promising activity for the drug in KRAS-mutated metastatic colorectal cancer, and biomarker-defined patient subgroups with castration-resistant prostate cancer and AML.

Mutated KRAS protein has been notoriously difficult to target with drugs, but MD Anderson researchers are trying to get at KRAS mRNA using exosomes.

The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.

The findings should spur cancer centers to review testing rates and address barriers, said experts from Hackensack University, Cota Healthcare, and Guardant Health. 

Drugmakers talked about precision oncology acquisitions, and a genetic testing firm discussed the use of artificial intelligence in predicting treatment response.

Among the firms presenting, drugmakers, speciality biotechs, and genetic testing firms provided an update on their precision oncology development programs.

The companies will develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer.

At least one drugmaker is planning to submit for FDA approval of its KRAS inhibitor based on data from Phase I/II, single-arm trial in heavily pretreated lung cancer patients.

Pages